×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| ALEMBIC PHARMACEUTICALS LTD. | 15019.6 | 1035.2 | 14941.7 | 5.27 | 18,620 | 31.4 |
| NEULAND LABORATORIES LTD. | 3006.09 | 137.08 | 2927.53 | 10.68 | 18410 | 140.0 |
| 530019 | 602.0 | 58.0 | 595.0 | 0.26 | 17522 | 36.0 |
ALEMBIC PHARMACEUTICALS LIMITED, with Security Code 533573, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,310.2 | 1,307.1 | 1,332.3 | 1,478.8 | 1,588.4 | 1,474.6 | 1,475.6 | 1,580.3 | 1,406.1 | 1,494.2 |
| Expenses | 1,086.0 | 1,137.9 | 1,166.5 | 1,271.4 | 1,251.2 | 1,186.4 | 1,184.1 | 1,320.9 | 1,226.3 | 1,280.4 |
| Operating Profit | 224.2 | 169.2 | 165.7 | 207.5 | 337.1 | 288.2 | 291.4 | 259.5 | 179.8 | 213.7 |
| OPM % | 17.11% | 12.94% | 12.44% | 14.03% | 21.23% | 19.54% | 19.75% | 16.42% | 12.79% | 14.3% |
| Other Income | 0.6 | 2.0 | 11.8 | 9.0 | 3.3 | 7.2 | 3.1 | 28.9 | 15.5 | 7.8 |
| Interest | 14.7 | 13.6 | 14.3 | 15.4 | 14.7 | 10.1 | 12.7 | 18.3 | 21.8 | 22.6 |
| Depreciation | 65.8 | 73.5 | 65.8 | 67.2 | 69.1 | 69.1 | 68.7 | 70.1 | 69.7 | 73.4 |
| Profit before tax | 144.3 | 84.0 | 97.5 | 133.8 | 256.7 | 216.2 | 213.2 | 187.1 | 103.8 | 125.5 |
| Tax % | -17.4% | 55.4% | 0% | 0% | -9.1% | -6.6% | 17.4% | -17.1% | -17.3% | 17.5% |
| Net Profit | 119.1 | 130.6 | 97.5 | 133.8 | 233.2 | 201.9 | 176.2 | 165.8 | 85.8 | 103.5 |
| EPS in Rs | 6.06 | 6.64 | 4.96 | 6.81 | 11.87 | 10.27 | 8.96 | 8.43 | 4.37 | 5.27 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,509.0 | 1,406.4 | 1,486.1 | 1,594.9 | 1,630.6 | 1,517.0 | 1,561.7 | 1,648.0 | 1,692.7 | 1,769.6 |
| Expenses | 1,273.9 | 1,202.7 | 1,287.5 | 1,387.2 | 1,364.3 | 1,257.3 | 1,324.9 | 1,408.7 | 1,432.5 | 1,498.4 |
| Operating Profit | 235.2 | 203.8 | 198.7 | 207.7 | 266.3 | 259.7 | 236.8 | 239.3 | 260.2 | 271.3 |
| OPM % | 15.58% | 14.49% | 13.37% | 13.03% | 16.33% | 17.12% | 15.16% | 14.52% | 15.37% | 15.33% |
| Other Income | 0.4 | 0.9 | 11.7 | 10.2 | 2.9 | 3.6 | 2.1 | 29.6 | 9.5 | 14.2 |
| Interest | 14.6 | 14.4 | 14.4 | 15.7 | 15.2 | 10.9 | 13.2 | 18.8 | 22.3 | 24.5 |
| Depreciation | 66.5 | 74.1 | 66.2 | 67.6 | 69.4 | 69.5 | 69.0 | 70.5 | 70.0 | 69.0 |
| Profit before tax | 154.5 | 116.2 | 129.8 | 134.6 | 184.6 | 182.8 | 156.7 | 166.7 | 177.4 | 192.0 |
| Tax % | -19.4% | 29.2% | -7.1% | 1.4% | -2.2% | -2.5% | -14.4% | 15.2% | 22.6% | -18.3% |
| Net Profit | 121.9 | 152.6 | 120.6 | 136.6 | 180.5 | 178.2 | 134.5 | 153.1 | 137.7 | 156.6 |
| EPS in Rs | 6.2 | 7.76 | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.79 | 7.01 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -13% |
| 3 Years: | -3% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 2% |
| 3 Years: | 9% |
| 1 Year: | 1% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 8% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -7% |
| 3 Years: | 3% |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 2% |
| 3 Years: | 9% |
| 1 Year: | 1% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|